{
    "clinical_study": {
        "@rank": "142799", 
        "arm_group": [
            {
                "arm_group_label": "Thealoz", 
                "arm_group_type": "Experimental", 
                "description": "Treatment with Thealoz (Trehalose) 3% for 1 month"
            }, 
            {
                "arm_group_label": "Treatment with Thealoz\u00b4s vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Treatment with Thealoz\u00b4s vehicle for 1 month"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if Thealoz is effective in Dry Eye Syndrome\n      exposed to controlled adverse environmental conditions."
        }, 
        "brief_title": "Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Moderate Dry Eye Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Man/woman \u2265 18 years old, able to freely give consent to participate in the study\n\n          -  Fluorescein corneal staining \u2265 1 and \u2264 3 in Oxford Scales\n\n          -  At least 2 of the following tests altered:\n\n          -  Ocular Surface Disease Index (OSDI) Test symptoms between 12 and 40\n\n          -  BUT \u226410 seconds\n\n          -  Lissamine green conjunctival staining \u2265 1\n\n          -  Schirmer Test without anesthesia \u2264 5 mm\n\n          -  Informed consent signed\n\n          -  Data protection consent signed\n\n        Exclusion Criteria:\n\n          -  Sensitivity or known intolerance to any of the product used in the study\n\n          -  Story of ocular infections or severe ocular inflammation within the 6 previous months\n             to study inclusion\n\n          -  Any active ocular pathology other than Dry Eye Syndrome\n\n          -  Any traumatize or ocular surgery that may affect corneal sensitivity and/or normal\n             tear distribution (e.g. cataract surgery, refractive surgery) within the 6 previous\n             months to study inclusion\n\n          -  Use of contact lenses in the 3 previous months to study inclusion\n\n          -  Use of any ocular topical medications other than the treatment for Dry Eye Syndrome\n\n          -  Ocular treatment for Dry Eye Syndrome with corticosteroids 1 month before inclusion\n             visit or  Cyclosporin A 3 months before inclusion\n\n          -  Diagnosis of Rosacea or Severe Blepharitis (associated to systemic or ocular\n             pathologies) Any severe uncontrolled systemic disease that may affect the eye (except\n             for primary or secondary Sj\u00f6gren)\n\n          -  Start, discontinuation or change within the study of the dosage of antihistaminics,\n             cholinergic agents, beta blockers, anti depressants or any other systemic drugs with\n             potential effects in the tear film\n\n          -  No pregnant or breastfeeding women is allowed to participate in the study.\n             Childbearing potential women must use contraceptive means during the whole study.\n\n          -  Participation in another clinical trial in the last 30 days before study inclusion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742884", 
            "org_study_id": "IOBA-Thea-001-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Thealoz", 
                "description": "Instillation of 1 drop of Thealoz", 
                "intervention_name": "Thealoz", 
                "intervention_type": "Other", 
                "other_name": "Thealoz, Trehalose"
            }, 
            {
                "arm_group_label": "Treatment with Thealoz\u00b4s vehicle", 
                "description": "1 drop of the vehicle will be instillated in the eye", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Other", 
                "other_name": "Instillation of Thealoz\u00b4s vehicle"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Dry Eye Syndrome", 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Valladolid", 
                    "country": "Spain", 
                    "zip": "47011"
                }, 
                "name": "IOBA - University of Valladolid"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz", 
        "overall_official": {
            "affiliation": "IOBA - University of Valladolid", 
            "last_name": "Maria Jesus Gonzalez, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Proportion of subjects with staining reduction within the treatment group vs proportion of staining reduction in control group", 
            "measure": "Proportion of patients with fluorescein corneal staining reduction of at least 1 point", 
            "safety_issue": "No", 
            "time_frame": "1 Month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742884"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Best Corrected Visual Acuity at Exit visit compared to baseline visit", 
                "measure": "Best Corrected Visual Acuity", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Pathological elevations of intraocular pressure from baseline", 
                "measure": "Intraocular pressure", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Presence of any pathological finding in eye fundus while the patient is in the study", 
                "measure": "Eye fundus alterations", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Changes in corneal thickness along the study", 
                "measure": "Corneal Pachymetry", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }
        ], 
        "source": "Instituto Universitario de Oftalmobiolog\u00eda Aplicada", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto Universitario de Oftalmobiolog\u00eda Aplicada", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}